PubMed

Defective metabolism of oxidized phospholipid by HDL from people with type 2 diabetes.

Mastorikou M, Mackness M, Mackness B.

Diabetes. 2006 Nov;55(11):3099-103.PMID: 17065348 [PubMed - indexed for MEDLINE]Related articlesFree article

Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides.

Mastorikou M, Mackness B, Liu Y, Mackness M.

Diabet Med. 2008 Sep;25(9):1049-55.PMID: 18937674 [PubMed - indexed for MEDLINE]Related articlesFree article

Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes.

Tsuzura S, Ikeda Y, Suehiro T, Ota K, Osaki F, Arii K, Kumon Y, Hashimoto K.

Metabolism. 2004 Mar;53(3):297-302.PMID: 15015140 [PubMed - indexed for MEDLINE]Related articles

High-density lipoprotein composition and paraoxonase activity in Type I diabetes.

Valabhji J, McColl AJ, Schachter M, Dhanjil S, Richmond W, Elkeles RS.

Clin Sci (Lond). 2001 Dec;101(6):659-70.PMID: 11724654 [PubMed - indexed for MEDLINE]Related articles

Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls.

Mackness B, Durrington PN, Boulton AJ, Hine D, Mackness MI.

Eur J Clin Invest. 2002 Apr;32(4):259-64.PMID: 11952811 [PubMed - indexed for MEDLINE]Related articles

Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus.

Flekac M, Skrha J, Zídková K, Lacinová Z, Hilgertová J.

Physiol Res. 2008;57(5):717-26. Epub 2007 Oct 11.PMID: 17949258 [PubMed - indexed for MEDLINE]Related articlesFree article

Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein.

Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M.

J Clin Invest. 1995 Dec;96(6):2882-91.PMID: 8675659 [PubMed - indexed for MEDLINE]Related articlesFree article

Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation.

Boemi M, Leviev I, Sirolla C, Pieri C, Marra M, James RW.

Atherosclerosis. 2001 Mar;155(1):229-35.PMID: 11223446 [PubMed - indexed for MEDLINE]Related articles

Paraoxonase1-192 polymorphism modulates the nonfatal myocardial infarction risk associated with decreased HDLs.

Sentí M, Tomás M, Marrugat J, Elosua R; REGICOR Investigators.

Arterioscler Thromb Vasc Biol. 2001 Mar;21(3):415-20.PMID: 11231922 [PubMed - indexed for MEDLINE]Related articlesFree article

The relationships between PON1 activity as well as oxLDL levels and coronary artery lesions in CHD patients with diabetes mellitus or impaired fasting glucose.

Lu C, Gao Y, Zhou H, Tian H.

Coron Artery Dis. 2008 Dec;19(8):565-73.PMID: 19005291 [PubMed - indexed for MEDLINE]Related articles

Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may Be due to the abnormal composition of HDL.

Gowri MS, Van der Westhuyzen DR, Bridges SR, Anderson JW.

Arterioscler Thromb Vasc Biol. 1999 Sep;19(9):2226-33.PMID: 10479666 [PubMed - indexed for MEDLINE]Related articlesFree article

Paraoxonase (Pon1) Q192R polymorphism and serum Pon1 activity in diabetic patients on maintenance hemodialysis.

Zhang B, Eto S, Fan P, Bian C, Shimoji E, Saito T, Saku K.

Clin Nephrol. 2003 Oct;60(4):257-65.PMID: 14579940 [PubMed - indexed for MEDLINE]Related articles

Paraoxonase and coronary heart disease.

Mackness MI, Mackness B, Durrington PN, Fogelman AM, Berliner J, Lusis AJ, Navab M, Shih D, Fonarow GC.

Curr Opin Lipidol. 1998 Aug;9(4):319-24. Review.PMID: 9739487 [PubMed - indexed for MEDLINE]Related articles

Susceptibility of low- and high-density lipoproteins from diabetic subjects to in vitro oxidative modification.

Julier K, Mackness MI, Dean JD, Durrington PN.

Diabet Med. 1999 May;16(5):415-23.PMID: 10342342 [PubMed - indexed for MEDLINE]Related articles

Inverse correlation of serum paraoxonase and homocysteine thiolactonase activities and antioxidant capacity of high-density lipoprotein with the severity of cardiovascular disease in persons with type 2 diabetes mellitus.

Lakshman MR, Gottipati CS, Narasimhan SJ, Munoz J, Marmillot P, Nylen ES.

Metabolism. 2006 Sep;55(9):1201-6.PMID: 16919539 [PubMed - indexed for MEDLINE]Related articles

Oxidative stress and high-density lipoprotein function in Type I diabetes and end-stage renal disease.

Kalogerakis G, Baker AM, Christov S, Rowley KG, Dwyer K, Winterbourn C, Best JD, Jenkins AJ.

Clin Sci (Lond). 2005 Jun;108(6):497-506.PMID: 15634192 [PubMed - indexed for MEDLINE]Related articles

Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy.

Mackness B, Durrington PN, Abuashia B, Boulton AJ, Mackness MI.

Clin Sci (Lond). 2000 Mar;98(3):355-63.PMID: 10677395 [PubMed - indexed for MEDLINE]Related articles

Arylesterase activity and antioxidant status depend on PON1-Q192R and PON1-L55M polymorphisms in subjects with increased risk of cardiovascular disease consuming walnut-enriched meat.

Nus M, Frances F, Librelotto J, Canales A, Corella D, Sánchez-Montero JM, Sánchez-Muniz FJ.

J Nutr. 2007 Jul;137(7):1783-8.PMID: 17585031 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of PON1 polymorphism on HDL antioxidant potential is blunted with aging.

Cherki M, Berrougui H, Isabelle M, Cloutier M, Koumbadinga GA, Khalil A.

Exp Gerontol. 2007 Aug;42(8):815-24. Epub 2007 Apr 24.PMID: 17532162 [PubMed - indexed for MEDLINE]Related articles

Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3.

Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, Reddy ST, Sevanian A, Fonarow GC, Fogelman AM.

J Lipid Res. 2000 Sep;41(9):1495-508.PMID: 10974057 [PubMed - indexed for MEDLINE]Related articlesFree article